Business Context and Reporting Period
This Form 6-K filing by Legend Biotech Corporation is dated August 6, 2026. The report discloses executive compensation details regarding the appointment of an Interim Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation.
Material Changes
On July 23, 2026, the Board of Directors appointed Alan Bash as Interim Chief Executive Officer and interim principal executive officer, effective July 24, 2026. This appointment follows a prior disclosure on July 27, 2026.
Management Commentary and Compensation Details
- Cash Compensation: The Compensation Committee approved a bi-weekly cash rate of $12,019 for Mr. Bash, effective July 27, 2026. This is in addition to his existing compensation as President of the CARVYKTI Business Unit.
- Equity Grant: A one-time grant of restricted stock units (RSUs) valued at $50,000 on the grant date of August 14, 2026, was approved.
- Vesting Schedule: The RSUs vest over a three-year period, with one-third vesting on each of the one-year, two-year, and three-year anniversaries of July 27, 2026, contingent on continued service.
Investor Verification Checklist
- Verify the total cash compensation impact of the $12,019 bi-weekly rate on the company's operating expenses.
- Confirm the grant date valuation of the $50,000 RSU award and its accounting treatment.
- Review the status of the permanent CEO search and the expected duration of the interim arrangement.
- Check for any subsequent filings regarding changes to Mr. Bash's role or compensation.